ZeroStack Corp. (ZSTK)
NASDAQ: ZSTK · Real-Time Price · USD
6.33
-0.75 (-10.59%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Company Description

ZeroStack Corp., through its subsidiary, Phatebo GmbH, engages in the pharmaceutical distribution business in Germany.

It operates through Commercial & Wholesale and Digital Assets segments. The company distributes a range of pharmaceutical goods and medical products to treat various health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants.

It also operates as a decentralized AI treasury company that invests in the future of AI infrastructure through strategic ownership of 0G tokens.

In addition, the company invests in early-stage companies. The company was formerly known as Flora Growth Corp. and changed its name to ZeroStack Corp. in January 2026.

ZeroStack Corp. was incorporated in 2019 and is based in Toronto, Canada.

ZeroStack Corp.
ZeroStack logo
Country Canada
Founded 2019
IPO Date May 11, 2021
Industry Asset Management
Sector Financials
Employees 21
CEO Daniel Reis-Faria

Contact Details

Address:
40 King Street W, Suite 2400
Toronto, ON M5H 3Y2
Canada
Phone 954-842-4989
Website zerostack.ai

Stock Details

Ticker Symbol ZSTK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001790169
CUSIP Number 98956L101
ISIN Number CA98956L1013
SIC Code 5122

Key Executives

Name Position
Daniel Reis-Faria Chief Executive Officer and Director
Michael Heinrich Executive Chairman
Dany Vaiman Chief Financial Officer
Dr. Manfred Ziegler Managing Director
Patrick Moloney Head of Product Development
Aaron Atin Corporate Secretary

Latest SEC Filings

Date Type Title
Apr 2, 2026 SCHEDULE 13D/A Filing
Mar 31, 2026 8-K Current Report
Feb 27, 2026 10-K Annual Report
Jan 29, 2026 8-K Current Report
Jan 27, 2026 424B5 Filing
Jan 27, 2026 FWP Free Writing Prospectus
Jan 27, 2026 424B3 Prospectus
Jan 26, 2026 EFFECT Notice of Effectiveness
Jan 8, 2026 S-3 Registration statement under Securities Act of 1933
Jan 6, 2026 8-K Current Report